Market Closed -
Nasdaq
04:00:00 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
4.53
USD
|
-3.72%
|
|
-3.41%
|
+9.95%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11.09
|
48.54
|
73.55
|
43.85
|
87.2
|
161.2
|
-
|
-
|
Enterprise Value (EV)
1 |
11.09
|
48.54
|
73.55
|
43.85
|
87.2
|
161.2
|
161.2
|
161.2
|
P/E ratio
|
-0.27
x
|
-1.49
x
|
-1.91
x
|
-0.61
x
|
-2.75
x
|
-4.43
x
|
-4.81
x
|
-12.4
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
627
x
|
4.27
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
627
x
|
4.27
x
|
EV / EBITDA
|
-742,366
x
|
-
|
-2,239,330
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.73
x
|
-
|
-2.5
x
|
-
|
-
|
-4.85
x
|
-3.46
x
|
-6.25
x
|
FCF Yield
|
-138%
|
-
|
-40%
|
-
|
-
|
-20.6%
|
-28.9%
|
-16%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,047
|
5,993
|
9,454
|
17,897
|
21,166
|
34,252
|
-
|
-
|
Reference price
2 |
10.60
|
8.100
|
7.780
|
2.450
|
4.120
|
4.705
|
4.705
|
4.705
|
Announcement Date
|
3/13/20
|
3/11/21
|
3/10/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.2571
|
37.72
|
EBITDA
|
-14.94
|
-
|
-32.84
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.53
|
-14.75
|
-33.09
|
-40.8
|
-27.25
|
-33.12
|
-36.35
|
-8.807
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-14,136.71%
|
-23.35%
|
Earnings before Tax (EBT)
1 |
-16.4
|
-14.73
|
-33.15
|
-42.35
|
-29.82
|
-34.3
|
-39.68
|
-9.422
|
Net income
1 |
-16.4
|
-14.73
|
-33.15
|
-42.35
|
-29.82
|
-33.94
|
-37.16
|
-9.422
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-14,452.49%
|
-24.98%
|
EPS
2 |
-39.80
|
-5.420
|
-4.080
|
-4.000
|
-1.500
|
-1.061
|
-0.9786
|
-0.3800
|
Free Cash Flow
1 |
-15.27
|
-
|
-29.44
|
-
|
-
|
-33.21
|
-46.56
|
-25.79
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-18,106.09%
|
-68.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/13/20
|
3/11/21
|
3/10/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-6.693
|
-7.115
|
-7.226
|
-10.07
|
-12.64
|
-10.86
|
-8.578
|
-7.714
|
-6.572
|
-4.386
|
-6.254
|
-7.149
|
-9.246
|
-10.95
|
-11.02
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-6.691
|
-7.151
|
-7.573
|
-10.47
|
-13.08
|
-11.23
|
-8.992
|
-8.239
|
-7.108
|
-5.476
|
-6.995
|
-7.418
|
-9.679
|
-11.78
|
-11.26
|
Net income
1 |
-6.691
|
-7.151
|
-7.573
|
-10.47
|
-13.08
|
-11.23
|
-8.992
|
-8.239
|
-7.108
|
-5.476
|
-6.537
|
-7.431
|
-9.528
|
-11.23
|
-11.26
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7100
|
-0.7600
|
-0.8000
|
-1.080
|
-1.350
|
-0.8300
|
-0.5000
|
-0.4300
|
-0.3400
|
-0.2600
|
-0.2517
|
-0.2283
|
-0.2817
|
-0.3050
|
-0.2800
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/10/22
|
5/12/22
|
8/11/22
|
11/14/22
|
3/16/23
|
5/9/23
|
8/14/23
|
11/9/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-15.3
|
-
|
-29.4
|
-
|
-
|
-33.2
|
-46.6
|
-25.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.05
|
-
|
-
|
-
|
-
|
0.26
|
0.31
|
0.38
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
122.11%
|
1.01%
|
Announcement Date
|
3/13/20
|
3/11/21
|
3/10/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
4.705
USD Average target price
19.75
USD Spread / Average Target +319.77% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.95% | 161M | | +23.37% | 46.71B | | +48.83% | 41.8B | | -0.94% | 41.52B | | -5.86% | 29.55B | | +11.29% | 25.78B | | -20.92% | 19.26B | | +3.20% | 12.14B | | -2.67% | 12.08B | | +30.23% | 11.98B |
Other Biotechnology & Medical Research
|